The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS)
摘要:
By careful analysis of experimental X-ray ligand crystallographic protein data across several inhibitor series we have discovered a novel, potent and selective series of iNOS inhibitors exemplified by compound 8. (C) 2011 Elsevier Ltd. All rights reserved.
Copper-Catalyzed Asymmetric Reductions of Aryl/Heteroaryl Ketones under Mild Aqueous Micellar Conditions
作者:David M. Fialho、Elham Etemadi-Davan、Olivia C. Langner、Balaram S. Takale、Amol Gadakh、Ganesh Sambasivam、Bruce H. Lipshutz
DOI:10.1021/acs.orglett.1c00746
日期:2021.5.7
Enantioselective syntheses of nonracemic secondary alcohols have been achieved in an aqueous micellar medium via copper-catalyzed (Cu(OAc)2·H2O/(R)-3,4,5-MeO-MeO-BIPHEP) reduction of aryl/heteroarylketones. This methodology serves as a green protocol to access enantio-enriched alcohols under mild conditions (0–22 °C) using a base metal catalyst, together with an inexpensive, innocuous, and convenient
非消旋仲醇的对映选择性合成已通过铜催化的(Cu(OAc)2 ·H 2 O /(R)-3,4,5-MeO-MeO-MePH-BIPHEP)还原芳基/杂芳基在胶束水溶液中实现酮。这种方法学是一种绿色的方案,可使用贱金属催化剂以及廉价,无害且方便的化学计量氢化物源(PMHS)在温和的条件下(0-22°C)获取对映体富集的醇。形成的仲醇产品的收率好至极好,ee值大于90%。
Novel use of phenylheteroakylamine derivatives
申请人:——
公开号:US20030158185A1
公开(公告)日:2003-08-21
There is disclosed the use of a compound of formula (I) wherein R
1
, R
2
, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.
[EN] TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS<br/>[FR] COMPOSÉS DE TÉTRAHYDROPYRIMIDODIAZÉPINE ET DE TÉTRAHYDROPYRIDODIAZÉPINE POUR LE TRAITEMENT DE LA DOULEUR ET DES AFFECTIONS ASSOCIÉES À LA DOULEUR
申请人:ESTEVE LABOR DR
公开号:WO2017191304A1
公开(公告)日:2017-11-09
The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially α2δ-1 subunit of voltage-gated calcium channels or dual activity towards subunit α2δ of voltage-gated calcium channels (VGCC), especially α2δ-1 subunit of voltage-gated calcium channels, and noradrenaline transporter (NET). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments. (I)
New hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (1), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.
New hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.